Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoustic Cluster Therapy with mFOLFIRINOX in Locally Advanced Pancreatic Cancer
NCT06850623Phase 2Recruiting
- Sponsor
- EXACT Therapeutics AS
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of PS101 in pancreatic adenocarcinoma (PDAC), sponsored by EXACT Therapeutics AS. Primary endpoint: Overall Response Rate at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
PS101
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06850623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850623.